SB 271046

Cat. No.:	HY-14336
CAS No.:	209481-20-9
Molecular Formula:	$C_{20}H_{22}ClN_3O_3S_2$
Molecular Weight:	451.99
Target:	5-HT Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	SB 271046 is a potent, selective and orally active 5-HT6 receptor antagonist with a pK_i of 8.92-9.09. SB 271046 show >200-fold selective for the 5-HT6 receptor over other receptors, binding sites and ion channels. SB 271046 has anticonvulsant activity[1].
IC_{50} & Target	5-HT_6 Receptor 8.92-9.09 (pKi)
In Vitro	In functional studies on human 5-HT6 receptors SB 271046 competitively antagonized 5-HT-induced stimulation of adenylyl cyclase activity with a pA_2 of 8.71[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	SB 271046 produces an increase in seizure threshold over a wide-dose range in the rat maximal electroshock seizure threshold (MEST) test, with a minimum effective dose of ⊠0.1 mg/kg p.o. and maximum effect at 4 h post-dose. The level of anticonvulsant activity achieved correlated well with the blood concentrations of SB 271046 (EC_{50} of 0.16 μM) and brain concentrations of 0.01-0.04 μM at C_{max}[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. C Routledge, et al. Characterization of SB-271046: a potent, selective and orally active 5-HT(6) receptor antagonist. Br J Pharmacol. 2000 Aug;130(7):1606-12.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA